Double-blind Comparative Study of TAK-875
This study has been completed.
Sponsor:
Takeda Pharmaceutical Company Limited
Information provided by (Responsible Party):
Takeda ( Takeda Pharmaceutical Company Limited )
ClinicalTrials.gov Identifier:
NCT01433393
First received: September 12, 2011
Last updated: November 7, 2012
Last verified: November 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate the efficacy and safety of treatment with TAK-875 in diabetic patients.
| Condition | Intervention | Phase |
|---|---|---|
|
Diabetes Mellitus |
Drug: TAK-875 Drug: Placebo |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Parallel Assignment |
Resource links provided by NLM:
Further study details as provided by Takeda:
Primary Outcome Measures:
- HbA1c [ Designated as safety issue: No ]
| Enrollment: | 192 |
| Study Completion Date: | September 2012 |
| Primary Completion Date: | September 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: TAK-875 25 mg | Drug: TAK-875 |
| Experimental: TAK-875 50 mg | Drug: TAK-875 |
| Placebo Comparator: Placebo | Drug: Placebo |
Eligibility| Ages Eligible for Study: | 20 Years and older |
| Genders Eligible for Study: | Both |
Criteria
Inclusion Criteria:
- The participant is an outpatient.
- The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
Exclusion Criteria:
- The participant has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease.
- The participant is considered ineligible for the study for any other reason by the investigator or sub-investigator.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01433393
Locations
| Japan | |
| Kisarazu-shi, Chiba, Japan | |
| Matsuyama-shi, Ehime, Japan | |
| Fukuoka-shi Nishi-ku, Fukuoka, Japan | |
| Kasuga-shi, Fukuoka, Japan | |
| Naka-shi, Ibaragi, Japan | |
| Tsuchiura-shi, Ibaragi, Japan | |
| Takamatsu-shi, Kagawa, Japan | |
| Kyoto-shi Fushimi-ku, Kyoto, Japan | |
| Nagasaki-shi, Nagasaki, Japan | |
| Kashihara-shi, Nara, Japan | |
| Kashiwara-shi, Osaka, Japan | |
| Osaka-shi Tsurumi-ku, Osaka, Japan | |
| Sakai-shi Nishi-ku, Osaka, Japan | |
| Shimotsuke-shi, Tochigi, Japan | |
| Chiyoda-ku, Tokyo, Japan | |
| Itabashi-ku, Tokyo, Japan | |
| Ota-ku, Tokyo, Japan | |
| Shinjuku-ku, Tokyo, Japan | |
| Toshima-ku, Tokyo, Japan | |
Sponsors and Collaborators
Takeda Pharmaceutical Company Limited
More Information
No publications provided
| Responsible Party: | Takeda ( Takeda Pharmaceutical Company Limited ) |
| ClinicalTrials.gov Identifier: | NCT01433393 History of Changes |
| Other Study ID Numbers: | TAK-875/CCT-003, U1111-1124-1518, JapicCTI-111604 |
| Study First Received: | September 12, 2011 |
| Last Updated: | November 7, 2012 |
| Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Keywords provided by Takeda:
|
Drug Therapy |
Additional relevant MeSH terms:
|
Diabetes Mellitus Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
ClinicalTrials.gov processed this record on June 17, 2013